報價延遲最少15分鐘:2024/12/25 00:14 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
34.19 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
11.66/-6.39
|
|
企業價值
2.07B
|
| 資產負債 |
|
每股賬面淨值
28.52
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
26.82M
|
|
每股收益
0.42
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 00:14 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |